Pasar al contenido principal

ANALISIS Y MEJORA DE LA ADECUACION DE LA PRESCRIPCION DE QUIMIOTERAPIA AL FINAL DE LA VIDA

PI18/00034

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Centro realización IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer, A Mapping Review and Evidence Gap Map

  • Requeijo, Carolina|||0000-0003-3479-4550
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Meza, Nicolás|||0000-0001-9505-0358
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Salazar, Josefina|||0000-0002-6448-5946
  • Santero, Marilina|||0000-0001-5371-0979
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Rodríguez-Grijalva, Gerardo
  • Selva, Anna|||0000-0002-2754-3158
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Despite being commonly recommended, the impact of anticancer drugs (ACDs) on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) may not have been sufficiently assessed. We aim to identify and map the evidence regarding ACDs versus best supportive care (BSC) for advanced HBCs, considering patient-centered outcomes. In this mapping review, we included systematic reviews, randomized controlled trials, quasi-experimental, and observational studies comparing ACDs (chemotherapy, immunotherapy, biological/targeted therapy) versus BSC for advanced HBCs. We searched MEDLINE (PubMed), EMBASE (Ovid), Cochrane Library, Epistemonikos, PROSPERO and clinicaltrials.gov for eligible studies. Two reviewers performed the screening and data extraction processes. We developed evidence maps for each type of cancer. We included 87 studies (60 for advanced liver cancer and 27 for gallbladder or bile duct cancers). Most of the evidence favored ACDs for survival outcomes, and BSC for toxicity. We identified several evidence gaps for non-survival outcomes, including quality of life or quality of end-of-life care. Patient-important outcomes beyond survival in advanced HBCs are insufficiently assessed by the available evidence. Future studies need to address these gaps to better inform decision-making processes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Systemic oncological treatments in patients with advanced pancreatic cancer: a scoping review and evidence map

  • Salazar, Josefina|||0000-0002-6448-5946
  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Meza, Nicolás|||0000-0001-9505-0358
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Rodríguez-Grijalva, Gerardo
  • Santero, Marilina|||0000-0001-5371-0979
  • Selva, Anna|||0000-0002-2754-3158
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Purpose: To identify, describe, and organise currently available evidence regarding systemic oncological treatments (SOTs) (chemotherapy, targeted/biological therapies, and immunotherapy) compared to best supportive care (BSC) for patients with advanced pancreatic cancer (PC). Methods: We conducted a scoping review and evidence mapping, adhering to PRISMA-ScR checklist. We searched MEDLINE, EMBASE, Cochrane Library, Epistemonikos, PROSPERO, and clinicaltrials.gov for eligible studies. We included systematic reviews (SRs), randomised controlled trials (RCTs), quasi-experimental, and observational studies evaluating SOTs compared to BSC or no treatment in patients with advanced PC. Two independent reviewers performed the screening process and data extraction. We developed evidence maps as an interactive visualization display, including the assessed interventions and outcomes. Results: Of the 50,601 records obtained from our search, we included 43 studies: 2 SRs, 16 RCTs, 4 quasi-experimental studies, 20 observational studies, and 1 protocol for a quasi-experimental study. Forty-two studies reported survival-related outcomes and most favoured SOTs, while fve reported toxicity and most favoured BSC. Other patient-centred outcomes, such as quality of life, were scarcely reported. Conclusions: This study highlights the current evidence gaps in studies assessing treatments for patients with advanced PC, mainly the lack of reports of non-survival-related outcomes, pointing out research areas that need further attention to make better recommendations for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers, An Overview of Systematic Reviews

  • Pérez Bracchiglione, Javier Andrés|||0000-0001-8738-2184
  • Rodríguez-Grijalva, Gerardo
  • Requeijo, Carolina|||0000-0003-3479-4550
  • Santero, Marilina|||0000-0001-5371-0979
  • Salazar, Josefina|||0000-0002-6448-5946
  • Salas-Gama, Karla|||0000-0003-4845-4899
  • Meade, Adriana-Gabriela|||0000-0002-7572-3524
  • Antequera, Alba|||0000-0002-1670-6302
  • Auladell-Rispau, Ariadna|||0000-0002-0364-4827
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Solà Arnau, Ivan|||0000-0003-0078-3706
  • Urrútia, Gerard|||0000-0002-8850-0960
  • Acosta-Dighero, Roberto|||0000-0002-2372-6088
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Hepatobiliary cancers (that include hepatocellular carcinoma, intrahepatic or extrahepatic cholangiocarcinoma and gallbladder cancer) are usually treated with systemic oncological treatments (i.e., chemotherapy, immunotherapy and biological or targeted therapies) mainly due to their improvement in survival. However, the trade-off between these therapies and usual practice supportive care is not clear, and other outcomes beyond survival should be considered in advanced stages, such as quality of life or symptom control. The present study is part of a wider project aiming to conduct broad evidence syntheses assessing the effects of systemic oncological treatments versus usual practice supportive care for patients with advanced non-intestinal digestive cancers. We performed an overview of systematic reviews assessing the effects of systemic oncological treatments versus usual practice supportive care for patients with primary advanced hepatobiliary cancer. We found evidence that for these patients (specifically for advanced hepatocellular carcinoma), systemic oncological treatments tend to improve survival at the expense of greater toxicity. Much of systematic reviews included was of low quality and highly overlapped. Nevertheless, the evidence we found failed to report other important outcomes that could be critical for decision making, including quality of life or symptom control. Future research assessing these patient-important outcomes is needed. Background: The trade-off between systemic oncological treatments (SOTs) and UPSC in patients with primary advanced hepatobiliary cancers (HBCs) is not clear in terms of patient-centred outcomes beyond survival. This overview aims to assess the effectiveness of SOTs (chemotherapy, immunotherapy and targeted/biological therapies) versus UPSC in advanced HBCs. Methods: We searched for systematic reviews (SRs) in PubMed, EMBASE, the Cochrane Library, Epistemonikos and PROSPERO. Two authors assessed eligibility independently and performed data extraction. We estimated the quality of SRs and the overlap of primary studies, performed de novo meta-analyses and assessed the certainty of evidence for each outcome. Results: We included 18 SRs, most of which were of low quality and highly overlapped. For advanced hepatocellular carcinoma, SOTs showed better overall survival (HR = 0.62, 95% CI 0.55-0.77, high certainty for first-line therapy; HR = 0.85, 95% CI 0.79-0.92, moderate certainty for second-line therapy) with higher toxicity (RR = 1.18, 95% CI 0.87-1.60, very low certainty for first-line therapy; RR = 1.58, 95% CI 1.28-1.96, low certainty for second-line therapy). Survival was also better for SOTs in advanced gallbladder cancer. No outcomes beyond survival and toxicity could be meta-analysed. Conclusion: SOTs in advanced HBCs tend to improve survival at the expense of greater toxicity. Future research should inform other patient-important outcomes to guide clinical decision making.